





Group (T1P): time point 1, placebo




Group (T1B): time point 1, Bevacizumab






Group (T1V): time point 1, Vatalanib




Group (T1C): time point 1, combination (Bevacizumab + Vatalanib)







Group (T2P): time point 2, placebo



Group (T2B): time point 2, Bevacizumab



Group (T2V): time point 2, Vatalanib





Group (T2C): time point 2, combination (Bevacizumab + Vatalanib)

